Search This Blog

Tuesday, February 11, 2020

With The New Coronavirus, Should You Avoid Large Meetings Like The MWC?

Novel mobile technology may be desirable. But a novel mobile virus? Not so much.
Concerns about the latter, namely the new coronavirus (2019-NCoV), are apparently keeping some major tech companies like Amazon and Sony from attending this year’s edition of the Mobile World Congress (MWC). Indeed, what’s billed as “the largest mobile event in the world” may not be so large this year if fears of infection keep enough people away. So, the big question is, “Alexa, does this make sense? Are such fears really founded? Is avoiding such mass gatherings now a good idea?”
If you have somehow been on the toilet since mid-December 2019 without access to any mobile devices and are wondering “what outbreak,” here’s what’s been dominating the news: the ongoing 2019-NCoV outbreak. It started in Wuhan, China, at the end of last year and has already resulted in over 42,000 people being infected and over 1,000 dying. The rapid spread of this newly discovered and still rather mysterious virus has raised real legitimate concerns around the world. At the same time, it has sparked some unjustified panic, uncovered some, surprise, surprise, racism, and spawned a whole lot of misconceptions, as I described previously for Forbes.
The outbreak has also prompted Sony to make the following decision: “Sony has been closely monitoring the evolving situation following the novel coronavirus outbreak, which was declared a global emergency by the World Health Organization on January 30th, 2020. As we place the utmost importance on the safety and well-being of our customers, partners, media and employees, we have taken the difficult decision to withdraw from exhibiting and participating at MWC 2020 in Barcelona, Spain.”
So, no Sony. And no Ericsson, no LG, no Intel, and no Amazon. These are just some of the companies that are taking their toys and staying at home.
That’s obviously not great news for the GSMA, the organization that’s putting on this shindig from February 24 to 27. The GSMA has insisted that they have no plans of canceling the event and instead detailed in a press release the precautions that the MWC will take. The precautions seem fairly typical of what an experienced infection control specialist would recommend.
For example, one set of precautions will be trying to keep anyone who has a higher risk of being infected away from the event. This is reasonable as long as the screening criteria are scientifically-based and not something like “anyone who looks Asian.” Indeed, the screening criteria put forth by the GSMA are more based on a person’s history, which makes sense. If you are from China’s Hubei province, the epicenter of the outbreak, time to make other plans. You won’t be allowed into the MWC. That also applies if you’ve been in China, anywhere in China, within 14 days prior to the start of the MWC. That’s soon enough to be infected but not yet manifest symptoms.
Being from China shouldn’t be the only criteria, because after all the virus has spread beyond the country. Therefore, regardless of where you are from, you’ll still have to “self-certify” that you haven’t been in contact with anyone who’s infected. Oh, and if you are hot, meaning fever-wise and not looks-wise, routine temperature screening at the meeting may keep you from entering.
That’s not all. The GSMA has promised to do more cleaning and disinfecting than usual, especially in areas that get touched more often, and provide ways for attendees to clean and disinfect themselves. If you are wondering what this “wash your hands” thing is, the MWC will provide cleaning and hygiene reminders and training. Oh, and this should be welcome news if you’ve ever had to speak after a prior speaker “got to first base” with the microphone. The GSMA will have a “microphone disinfecting and change protocol for all speakers.” Yeah, having to use a moist microphone that smells like saliva isn’t too fun. All of these steps should become more standard at meetings in general.
Additional measures will include bolstering the number of security and medical personnel available and providing public health guidelines and advice to local businesses. Then, there’s the planned “no-handshake policy.” That will mean lots of waves, ‘sup head nods, one-finger points, winks and gun gestures, “all right, all right , all rights,” and deep meaningful stares instead. This, of course, will be encouraged and not strictly enforced. It’s not as if you will be escorted out if you have the audacity to actually shake someone’s hand.
Are all of these precautions comforting enough for you? Or will you go the way of Amazon and skip all such mass gatherings? Certainly, going to mass gatherings in Wuhan City would not be the wisest thing to do right now and may not even be possible given the quarantines that are occurring there. But, how about something like the MWC? If you haven’t figured it out from a map or your Uber app, Barcelona, Spain, is not right next to Wuhan, China. It is about 9,407 km away, which would be a really expensive Uber ride. The question then is should you avoid all mass gatherings, even those that are far, far away from the epicenter of the 2019-nCoV outbreak?
Well, let’s look at what’s actually happening with the outbreak. Sure, the 2019-nCoV has already spread beyond China as shown by the following AFP News Agency tweet :
And, yes, the numbers have been growing. But keep in mind, the vast majority of cases have still been in China. Twelve cases in the U.S., seven in Canada, four in Britain, 14 in Germany, one in Belgium, and 18 in Taiwan aren’t exactly huge numbers.
Plus, the MWC is far from the only mass gathering that will be occurring this month. Sporting events, church services, parties, massive Tinder gatherings, and other conferences will continue to bring together strangers to mix. For example, the World Clown Association Convention seems to be still on for early March. Surely, Amazon and other companies won’t be pulling their employees out of every meeting and gathering for all of February and beyond until the outbreak passes.
Are people more concerned about the MWC because of this statistic mentioned on the GSMA press release: typically 5-6% of all MWC attendees (that’s 5,000 to 6,000 people) have come from China? Perhaps. Remember, though, China has over 1.39 billion people living on a piece of land that is over 9.38 million square miles. While there have been over 40,000 cases of infection in China, that is still only a small fraction of all the people in China. Believing that everyone from China may be infected with 2019-nCoV would be like believing that everyone from America puts Tide Pods in their mouths, not that the two are related.
Additionally, avoiding or cancelling mass gatherings may not do a whole lot to slow or mitigate epidemics caused by highly contagious respiratory viruses like the 2019-NCoV. As long as other interactions are still occurring at workplaces, schools, and the community, viruses that can be transmitted via respiratory droplets can still find other venues to spread. Just look at what our computational modeling found during the 2009 H1N1 influenza pandemic. For example, a publication in BMC Public Health detailed a study that was a collaboration between our PHICOR team and a team that at the time was at Georgia Tech University (Pengyi Shi, PhD, Pinar Keskinocak, PhD, and Julie L Swann, PhD). The study entailed developing a computer model that simulated the population of Georgia (the state and not the country) and their daily activities and movements to and from different locations. Simulation experiments then introduced a novel flu virus into the population. No one had vaccine-induced immunity to this virus, which meant that the virus could spread rather rapidly, sort of like the new coronavirus but not exactly. We ran simulation experiments with and without canceling all mass gatherings at varying times. That’s all large meetings, concerts, and sporting events in the state of Georgia. In most situations, canceling such events did little to slow or reduce the spread of the virus. They proved useful only when the cancellations occurred within the 10-day time period before the peak of the epidemic occurred. In such cases, canceling such gatherings couldn’t really stop the epidemic but could decrease the number of people who get infected by as much as 10%.
At this point in time, with most of the cases still being in China, canceling or avoiding mass gatherings far away from the epicenter may not be the most effective way of preventing the spread of the virus. Instead, it’s probably better to have more universal adoption of the strategies outlined by the GSMA. Again, this includes identifying those who may be at greater risk for carrying the virus based on their history, enhanced cleaning and disinfecting, encouraging hand washing, and minimizing activities that may transfer the virus such as trading disgusting, spit-drenched microphones and dirty, dirty handshakes.
When determining whether to go to a mass gathering, look at all the risks. If you are still mixing with other people in other ways, you may not be really decreasing your risk of getting infected by that much. And currently, your risk of catching the 2019-NCoV is still pretty low if you are not close to Wuhan, China. Practicing good infection control measures and not staying weirdly close to people remain the best ways to protect yourself regardless of where you go. Like it or not, our world is already too heavily connected and mobile to make avoiding certain groups of people the smart thing to do.
https://www.forbes.com/sites/brucelee/2020/02/10/new-coronavirus-and-mobile-world-congress-withdrawals-should-you-avoid-mass-gatherings/#1617e08d4c73

Ligand to Acquire Icagen Assets, Partner Programs, Tech, Updates Outlook

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the signing of an agreement whereby Ligand will acquire the core assets of Icagen, Inc.’s North Carolina operations, including partnered programs, proprietary ion channel screening and assay platforms, x-ray fluorescence capabilities, custom screening technologies and novel unpartnered preclinical-stage molecules for $15 million in cash. Icagen will also be entitled to receive up to an additional $25 million of cash payments based on certain revenue achievements.
The acquired assets include Icagen’s partnered programs with Roche focused on neurological diseases, and with the Cystic Fibrosis Foundation (CFF) focused on cystic fibrosis. Ligand is also acquiring six Icagen preclinical-stage internal programs targeting diabetes, Parkinson’s disease, pain and other disorders.
“This is an ideal transaction for Ligand, providing a valuable technology platform with high-value partnerships within a cash-flow positive and profitable business. Icagen has built deep expertise focused on ion channels and transporters to support target identification and evaluation, and has an established track record in ion channel drug discovery from screening to lead optimization,” said John Higgins, Chief Executive Officer of Ligand. “We expect these capabilities will be synergistic across multiple technology platforms at Ligand, particularly with Vernalis and in novel OmniAb antibody discovery targeting ion channels and transporters. We are very pleased with how 2020 is starting, and we look forward to delivering more opportunities with investment in our business and further acquisitions.”
Richard Cunningham, Chief Executive Officer of Icagen, commented, “I am excited that Ligand will be continuing to advance the progress Icagen has made with our technologies, and am proud of our entire team’s accomplishments to date. In addition to the expertise in ion channel drug discovery, the expertise that Ligand is acquiring from Icagen in medicinal chemistry, in silico and computational chemistry will complement and expand the drug-discovery efforts currently ongoing at Ligand.”
This transaction is subject to certain closing conditions, including a vote of Icagen stockholders, and is expected to close in April 2020. Slides that provide additional information related to this transaction are available here on the Ligand website.
Including this acquisition, Ligand now expects 2020 total revenues to be $128 million, up from $121 million projected previously. This new guidance assumes approximately $7 million of revenue from the Icagen business in 2020. In 2020, adjusted earnings per diluted share is now projected to be $3.45, up from $3.40 previously.
The contribution of the acquired Icagen assets and business to Ligand is currently expected to increase in 2021, with revenues of approximately $12 million and adjusted earnings per diluted share of approximately $0.25.
https://www.ligand.com/news-events/press-releases/detail/405/

CDC releases nearly 200 Americans from quarantine

The Centers for Disease Control and Prevention (CDC) released 195 Americans from quarantine on Tuesday, two weeks after they were evacuated from Wuhan, China, the epicenter of a coronavirus outbreak.
The individuals, who are mostly State Department employees and their family members, were quarantined at March Air Reserve Base in Riverside, Calif.
“Today is the 14th day of the quarantine of the individuals who were on the first charter flight returning from Wuhan province and they are currently being assessed to make sure they remain symptom-free, and then we hope they will be released to travel to their home today,” Dr. Anne Schuchat, principal deputy director of the CDC, told reporters Tuesday ahead of the release.
The State Department has evacuated more than 800 individuals from China since the outbreak began last month. Many of those individuals have been quarantined at military bases throughout the country.
More than 40,000 cases of the coronavirus have been confirmed throughout the world, with only 319 cases occurring outside of China.
Thirteen cases have been confirmed in the U.S., but 11 of those individuals had recently traveled to China.
The CDC has implemented a number of aggressive measures to prevent the virus from spreading in the U.S., including quarantining of Americans arriving from Wuhan and banning foreign nationals from entering the country if they have recently traveled within China.
These measures “[have] slowed the arrival of this virus” into the U.S., Schuchat said Tuesday.
https://thehill.com/policy/healthcare/482567-cdc-expects-to-release-nearly-200-americans-from-quarantine-tuesday

Injectable drug for faster healing of bone fractures prepares for clinical trials

One in three adults aged 60 and over suffering from a hip fracture dies within one year. Now, a Purdue University-affiliated startup is moving closer to the start of clinical trials for a novel injectable drug that is targeted to heal broken bones faster and strengthen weak bones.
The Purdue University discovered drug, NOV004, from Novosteo Inc. is unique in that it concentrates at the fracture site while reducing exposure to the rest of the body.
Novosteo, the startup developing the drug, was co-founded by father-son team Philip S. Low, the Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry, and Stewart A. Low, the company’s CSO and Visiting Scholar in Purdue’s Department of Chemistry. The treatment was developed in the Purdue laboratory of Low in the Purdue Institute of Drug Discovery. Currently there are 288 clinical trials performed or in process using Purdue-developed medical treatments at 4,841 sites across the globe.
Scott Salka, who recently joined the startup as executive chair, will use his 28 years of experience as a biotechnology entrepreneur to help Novosteo move its innovations from the laboratory to clinical trials and ultimately in to the hands of doctors and patients.
“We have been working on some amazing science with people truly dedicated to making a difference in reducing the mortality and improving the quality of life for our aging population,” said Salka. “We have completed preclinical studies with NOV004 and are looking to take it to clinical trials later this year.”
As CEO, Salka has successfully led efforts to advance novel drugs through preclinical and early clinical development, most recently at publicly traded Ampliphi, now Armata NYSE: ARMP. Prior to that he founded and served as CEO for both Ambit Biosciences, acquired by Daiichi Sankyo OTC: DSNKY, and Rakuten Medical.
Novosteo is already looking at the future use of the injectable-targeted drug for other applications, including dental implants, head and facial fractures, and hip and knee replacements. In addition, Novosteo has a pipeline of drugs for treating an array of musculoskeletal maladies. Salka will present some of the technology at Biocom’s Global Life Science Partnering Conference this month in La Jolla, California.
Novosteo’s technology is licensed through the Purdue Research Foundation Office of Technology Commercialization. The company also received entrepreneurial support from Purdue Foundry, an entrepreneurship and commercialization hub in Discovery Park District’s Convergence Center for Innovation and Collaboration where startups, entrepreneurs, innovators and companies can collaborate with Purdue to address global challenges in health, sustainability, IT and space.
The Purdue Institute of Drug Discovery is situated near the district, a $1 billion-plus long-term enterprise to support a transformational center of innovation on the western edge of the Purdue University campus. The district already includes a public airport with a 7,000-foot runway, and partnerships international companies including Rolls-Royce, Schweitzer Engineering Laboratories and Saab. Visit Discovery Park District.

Novosteo was founded to reduce the morbidity, mortality and loss of productivity associated with bone fractures. Based on discoveries of agents that accelerate bone regeneration and breakthroughs in methods to target these agents selectively to fracture surfaces, Novosteo has designed a series of fracture-targeted drugs that concentrate a drug’s healing power specifically at the fracture site, thereby greatly accelerating and improving the healing process. The mission of Novosteo is to reduce the debilitating and often life-threatening effects of bone fractures. More information is available on the Novosteo website.
https://www.eurekalert.org/pub_releases/2020-02/pu-idf021120.php

FDA accepts NDA for FibroGen anemia treatment

FibroGen (NASDAQ:FGEN) +4.4% after-hours following news that the Food and Drug Administration accepted its New Drug Application for roxadustat for the treatment of anemia of chronic kidney disease.
The filing of the roxadustat NDA triggers a $50M milestone payment from AstraZeneca (NYSE:AZN) to FibroGen.
Roxadustat is the first orally administered small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor accepted by the FDA for review for the treatment of anemia of CKD.
https://seekingalpha.com/news/3540861-fda-accepts-nda-for-fibrogen-anemia-treatment

Adamas Pharma higher after positive Gocovri trial data

Adamas Pharmaceuticals (NASDAQ:ADMS) has published trial data indicating its Gocovri has maintained its treatment effect on motor complications for at least two years.
Shares are up 1.8% after hours.
The Phase 3 open-label EASE LID 2 trial enrolled 223 patients and saw the positive effect in all subgroups, including those continuing treatment from prior double-blind trials, from placebo or amantadine immediate release, as well as those with dyskinesia receiving deep brain stimulation.
“These newly published results suggest that Gocovri may reduce dyskinesia and OFF as far out as 100 weeks, providing sustained benefits to patients with levodopa-induced dyskinesia,” says Dr. Jean Hubble, VP of Medical Affairs for Adamas.
https://seekingalpha.com/news/3540868-adamas-pharma-higher-after-positive-gocovri-trial-data

J&J teams up with BARDA to accelerate coronavirus vaccine development

Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical Companies expands its collaboration with the U.S. Department of Health & Human Services’ Biomedical Advanced Research and Development Authority (BARDA) aimed at accelerating the development of a vaccine against the coronavirus causing the current outbreak, COVID-19 (formerly 2019-nCoV).
Janssen and BARDA will both fund R&D costs and mobilize resources to more rapidly progress through the initial stages of development. BARDA will provide funding to support development into Phase 1 studies with options to provide additional funding to advance a promising candidate.
In parallel, Janssen will work to upscale production and manufacturing capacities, leveraging its AdVac and PER.C6 technologies.
Shares up 1% after hours.
https://seekingalpha.com/news/3540807-j-and-j-teams-up-barda-to-accelerate-coronavirus-vaccine-development